[Abstract] Glioblastoma (GBM) is the most common primary brain cancer in adults and has a poor prognosis. It is characterized by a high degree of cellular infiltration that leads to tumor recurrence, atypical hyperplasia, necrosis, and angiogenesis. Despite aggressive treatment modalities, current therapies are ineffective for GBM. Mouse GBM models not only provide a better understanding in the mechanisms of gliomagenesis, but also facilitate the drug discovery for treating this deadly cancer. A retroviral vector system that expresses PDGFBB (Platelet-derived growth factor BB) and inactivates PTEN (Phosphatase and tensin homolog) and P53 tumor suppressors provides a rapid and efficient induction of glioma in mice with full penetrance. In this protocol, we describe a simple and practical method for inducing GBM formation by retrovirus injection in the murine brain. This system gives a spatial and temporal control over the induction of glioma and allows the assessment of therapeutic effects with a bioluminescent reporter.
Note: Higher confluence can be a hindrance as cells don't have space to grow.
ii. 1 h before transfection, change media with fresh D10 media-4 ml per plate.
iii. Use the following table for 10 cm plates for transfection (Table 1) .
www.bio-protocol.org/e2404 iii. Then add it into the plates drop wise and gently shake.
iv. Incubate at 37 °C and 5% CO2 for 5 h.
Note: Do not keep longer as it can be toxic to the cells.
v. Discard the transfecting media and add fresh D10 10 ml per plate and incubate at 37 °C and 5% CO2 for 24 h. b. Pool the media from day 3 and day 4 and filter using 0.45 µm pore size filter.
Ultracentrifugation for viral concentration
a. We use Beckman Coulter rotor SW 32 Ti, which has capacity to hold six 38 ml open-end tubes. Balance the tubes to the maximum difference of 0.5 g and centrifuge at 68,300 x g (20,000 rpm) for 2 h at 4 °C. With each tube holding 30 ml, a total 360 ml of media can be centrifuged in one run. If required to run more media, discard the supernatant after 1st spin without disturbing the pellet add fresh media for 2nd run.
Note: Do not use the tubes filled less than half of its capacity which increases the risk of collapse.
b. Pour off the supernatant after the run and aspirate rest of the droplets from the wall without disturbing the pellet. for maintenance. Alternatively, use ketamine and xylazine combination which is injected intra-peritoneal.
e. Load the concentrated virus in syringe (e.g., 3 µl per each mouse to be injected) slowly avoiding bubbles and set it up on the holder in stereotaxic device.
f. Apply artificial tear ointment on exposed cornea to avoid drying. e. Adjust the stereotaxic device in relation to bregma as a reference and then use the coordinates depending on the age and area of brain to be targeted (e.g., for targeting the corpus callosum in adult mice, we used the coordinates: Anteroposterior + 0.2 mm, Lateral ± 0.5 mm and dorso-ventral 2.2 mm.
f. Mark the targeted area with surgical site marker.
g. Drill hole in bone using micro-drill being careful to avoid going too deep.
h. Lower the syringe needle 0.4-0.6 mm deeper to the desired depth (e.g., here 2.2 + 0.6 mm), wait for 1-2 min and retract back to desired depth to form a small pocket and slowly inject 1 μl of viral concentrate, wait for 1-2 min, retract 1 mm and inject 1 μl again. We usually inject 1-3 μl of viral concentrate in one adult mouse.
i. Slowly retract the needle to avoid leaking of the concentrate. n. Wash the needle with 70% ethanol and three times with sterile water.
Data analysis
The initial tumor growth can be noticed within 2-3 weeks in the brain monitored by in vivo bioluminescent imaging system such as IVIS Spectrum CT (PerkinElmer). Tumor-bearing mice normally survive for 3-6 weeks post injection depending on age at the time of injection. Neonatal 
